Sphincter preservation in distal CT2N0 rectal cancer after preoperative chemoradiotherapy

被引:3
|
作者
Wasserberg, Nir [1 ]
Kundel, Yulia [2 ,3 ]
Purim, Ofer [2 ,3 ]
Keidar, Andrei [1 ]
Kashtan, Hanoch [1 ]
Sadot, Eran [1 ]
Fenig, Eyal [2 ,3 ]
Brenner, Baruch [2 ,3 ]
机构
[1] Dept Surg B, IL-49100 Petah Tiqwa, Israel
[2] Rabin Med Ctr, Davidoff Canc Ctr, IL-49100 Petah Tiqwa, Israel
[3] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
关键词
T2 rectal cancer; Preoperative chemoradiotherapy; Sphincter preservation; Low anterior resection; Abdominoperineal resection; LYMPH-NODES; PRESERVING SURGERY; RADIATION-THERAPY; NEOADJUVANT CHEMORADIATION; MESORECTAL EXCISION; RADIOTHERAPY; RESECTION; NUMBER; SURVIVAL; INCREASES;
D O I
10.1186/s13014-014-0233-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Preoperative chemoradiotherapy is usually not indicated for cT2N0 rectal cancer. Abdominoperineal resection is the standard treatment for distal rectal tumors. The aim of the study was to evaluate the actual sphincter-preservation rate in patients with distal cT2N0 rectal cancer given neoadjuvant chemoradiotherapy. Methods: Data were retrospectively collected for all patients who were diagnosed with distal cT2N0 rectal cancer at a tertiary medical center in 2000-2008 and received chemoradiotherapy followed by surgery (5-7 weeks later). Results: Thirty-three patients (22 male) of median age 65 years (range, 32-88) were identified. Tumor distance from the anal verge ranged from 0 to 5 cm. R0 resection with sphincter preservation was accomplished in 22 patients (66%), with a 22% pathological complete response rate. Median follow-up time was 62 months (range 7-120). There were no local failures. Crude disease-free and overall survival were 82% and 86%, respectively. Factors associated with sphincter preservation were tumor location (OR = 0.58, p = 0.02, 95% CI = 0.37-0.91) and pathological downstaging (OR = 7.8, p = 0.02, 95% CI = 1.35-45.85). Chemoradiotherapy was well tolerated. Conclusion: High rates of sphincter preservation can be achieved after preoperative chemoradiotherapy for distal cT2N0 rectal cancer, with tolerable toxicity, without compromising oncological outcome.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Preoperative versus postoperative chemoradiotherapy in stage T3, N0 rectal cancer
    Deniz Tural
    Fatih Selcukbiricik
    Özcan Yıldız
    Olgun Elcin
    Sibel Erdamar
    Sabri Güney
    Fuat Demireli
    Evin Büyükünal
    Süheyla Serdengeçti
    International Journal of Clinical Oncology, 2014, 19 : 889 - 896
  • [42] Effects of preoperative chemoradiotherapy on anal sphincter functions and quality of life in rectal cancer patients
    Canda, Aras Emre
    Terzi, Cem
    Gorken, Ilknur B.
    Oztop, Ilhan
    Sokmen, Selman
    Fuzun, Mehmet
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2010, 25 (02) : 197 - 204
  • [43] Preoperative versus postoperative chemoradiotherapy in stage T3, N0 rectal cancer
    Tural, Deniz
    Selcukbiricik, Fatih
    Yildiz, Ozcan
    Elcin, Olgun
    Erdamar, Sibel
    Guney, Sabri
    Demireli, Fuat
    Buyukunal, Evin
    Serdengecti, Suheyla
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2014, 19 (05) : 889 - 896
  • [44] Effects of preoperative chemoradiotherapy on anal sphincter functions and quality of life in rectal cancer patients
    Aras Emre Canda
    Cem Terzi
    Ilknur B. Gorken
    Ilhan Oztop
    Selman Sokmen
    Mehmet Fuzun
    International Journal of Colorectal Disease, 2010, 25 : 197 - 204
  • [45] Distal margin requirements after preoperative chemoradiotherapy for distal rectal carcinomas:: Are ≤ 1 cm distal margins sufficient?
    Kuvshinoff, B
    Maghfoor, I
    Miedema, B
    Bryer, M
    Westgate, S
    Wilkes, J
    Ota, D
    ANNALS OF SURGICAL ONCOLOGY, 2001, 8 (02) : 163 - 169
  • [46] Genome landscapes of rectal cancer before and after preoperative chemoradiotherapy
    Yang, Jie
    Lin, Yuan
    Huang, Ying
    Jin, Jing
    Zou, Shuangmei
    Zhang, Xiaolong
    Li, Hongmin
    Feng, Ting
    Chen, Jinna
    Zuo, Zhixiang
    Zheng, Jian
    Li, Yexiong
    Gao, Ge
    Wu, Chen
    Tan, Wen
    Lin, Dongxin
    THERANOSTICS, 2019, 9 (23): : 6856 - 6866
  • [47] Oncologic Outcome After Preoperative Chemoradiotherapy in Patients With Pathologic T0 (ypT0) Rectal Cancer
    Jang, Tae Young
    Yu, Chang Sik
    Yoon, Yong Sik
    Lim, Seok-Byung
    Hong, Seung-Mo
    Kim, Tae Won
    Kim, Jong Hoon
    Kim, Jin Cheon
    DISEASES OF THE COLON & RECTUM, 2012, 55 (10) : 1024 - 1031
  • [48] Pathologic and clinical outcomes in cT2N0 esophageal cancer: A cohort study.
    Bhuchar, Gauri
    Altujjar, Mohammad
    Raja, Siva
    Murthy, Sudish C.
    Raymond, Daniel
    Videtic, Gregory M. M.
    McNamara, Michael J.
    Khorana, Alok A.
    Adelstein, David J.
    Sohal, Davendra
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [49] Optimal timing of surgery after preoperative chemoradiotherapy for rectal cancer
    Lars Påhlman
    Nature Reviews Clinical Oncology, 2009, 6 : 128 - 129
  • [50] KRAS mutation heterogeneity in rectal cancer after preoperative chemoradiotherapy
    Jo, P.
    Salendo, J.
    Kitz, J.
    Conradi, L. C.
    Azizian, A.
    Wolff, H. A.
    Grade, M.
    Stroebel, P.
    Ghadimi, M.
    Gaedcke, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 45 - 46